Study of RP-3500 (Camonsertib) With Niraparib or Olaparib in Advanced Solid Tumors

Phase 1/2 Terminated 156 enrolled Repare Therapeutics

Non-randomizedSequentialOpen-labelTreatment

Summary

The primary purpose of this study is to assess the safety and tolerability of niraparib or olaparib in combination with RP-3500 (camonsertib), in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) of RP-3500 (camonsertib) in combination with niraparib or olaparib, examine pharmacokinetics (PK) and assess anti-tumor activity.

Timeline

Start: 2021-07-21
Primary completion: 2024-11-13
Completion: 2024-11-13

Outcome

Outcome not reported

Stopped: “Sponsor decided to terminate study early therefore, the Phase 2 portion was not conducted”

Publications

Silverman IM, Schonhoft JD, Herzberg B, Yablonovitch A, Lagow E, Fiaux PC, Safabakhsh P, Sethuraman S, Ulanet D, Yang J, Kim I, Basciano P, Cecchini M, Lee E, Lheureux S, Fontana E, Carneiro BA, Reis-Filho JS, Yap TA, Zinda M, Rosen EY, Rimkunas V. Genomic and Epigenomic ctDNA Profiling in Liquid Biopsies from Heavily Pretreated Patients with DNA Damage Response-Deficient Tumors. Clin Cancer Res. 2025 Oct 1;31(19):4136-4149. doi: 10.1158/1078-0432.CCR-25-1248.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Camonsertib	Small molecule	—	Oral
Subject	Niraparib	Small molecule	—	—
Subject	Olaparib	Small molecule	—	—

Indications

No indication recorded.